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Abstract 
Background: To evaluate the prognostic value of peak serum lactate and lactate clearance at several time points in 
cardiogenic shock treated with temporary mechanical circulatory support (MCS) using veno-arterial extracorporeal 
membrane oxygenation (VA-ECMO) or Impella  CP®.
Methods: Serum lactate and clearance were measured before MCS and at 1 h, 6 h, 12 h, and 24 h post-MCS in 43 
patients at four tertiary-care centers in Southern Brazil. Prognostic value was assessed by univariable and multivariable 
analysis and receiver operating characteristic (ROC) curves for 30-day mortality.
Results: VA-ECMO was the most common MCS modality (58%). Serum lactate levels at all time points and lactate 
clearance after 6 h were associated with mortality on unadjusted and adjusted analyses. Lactate levels were higher 
in non-survivors at 6 h, 12 h, and 24 h after MCS. Serum lactate > 1.55 mmol/L at 24 h was the best single prognostic 
marker of 30-day mortality [area under the ROC curve = 0.81 (0.67–0.94); positive predictive value = 86%). Failure to 
improve serum lactate after 24 h was associated with 100% mortality.
Conclusions: Serum lactate was an important prognostic biomarker in cardiogenic shock treated with temporary 
MCS. Serum lactate and lactate clearance at 24 h were the strongest independent predictors of short-term survival.
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Background
Cardiogenic shock is a high-mortality condition with 
increasing incidence [1]. The hemodynamic impairment 
caused by cardiogenic shock triggers an inflammatory 
cascade, which leads to circulatory collapse and tissue 
perfusion impairment [2]. Lactate is a metabolic byprod-
uct of anaerobic glycolysis and a reliable marker of tissue 
hypoperfusion [3]. It has been used both as prognostic 
variable and as therapeutic target in different clinical sce-
narios of shock [4, 5]. Treating cardiogenic shock with 
MCS may enhance macro- and microcirculation, improv-
ing tissue perfusion [6].The increase in tissue oxygenation 
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might reduce lactate production, which makes it a good 
biomarker [7–9].
The judicious selection of patients eligible for MCS 
therapy is essential, since it increases cost exponentially 
and may be futile in advanced shock status [10]. Several 
risk scores have been proposed to establish prognosis and 
help in MCS selection in cardiogenic shock. However, 
these scores are known to be inaccurate and too complex 
to be used at bedside [11], especially in patients receiving 
MCS [12]. In this sense, arterial lactate is a widely avail-
able biomarker that can be used at bedside to evaluate 
prognosis [13]. Although any single lactate measurement 
might have prognostic value in patients with cardiogenic 
shock, it is unclear whether peak serum lactate, lactate 
clearance, or measurements obtained at any one time 
point post-MCS have the greatest prognostic predictive 
accuracy [5, 8, 14]. Recently, a large cohort of patients 
submitted to intra-aortic balloon pump (IABP) as treat-
ment of cardiogenic shock evaluated the prognostic role 
of arterial lactate in several time-points, showing that its 
measure after 8 h was superior to baseline and clearance 
values [13]. However, IABP provides a lower increase 
in cardiac output in comparison to other MCS such as 
Impella  CP® or veno-arterial extracorporeal membrane 
oxygenation (VA-ECMO) [6]. Previous studies on the 
role of arterial lactate in cardiogenic shock with MCS are 
heterogeneous in study population and device selected 
[8, 14, 15]. Moreover, the ideal cutoff lactate value to 
identify patients with better prognosis is yet to be estab-
lished in this scenario. Within this context, we conducted 
an observational study to evaluate the prognostic role of 
serum lactate measurements and lactate clearance over 
time in patients with several cardiogenic shock etiologies 
treated with temporary MCS.
Methods
Study population and design
This is a retrospective analysis of a cohort of cardiogenic 
shock patients treated with Impella  CP® or VA-ECMO 
between April 2017 and July 2019 at four tertiary centers 
in Southern Brazil. All centers were participants of the 
Qualificação do uso de Dispositivos de Assistência Cir-
culatória no SUS (Qualification for use of MCS devices 
in the Brazilian Unified Health System) project. Center 
selection criteria included tertiary centers with a cath-
eterization laboratory able to provide 24-h support and 
intensive care unit with a dedicated team for patients 
on temporary MCS. Eligibility criteria included patients 
in cardiogenic shock treated with MCS for whom com-
plete clinical records, serum lactate levels measured at 
pre-established time points, and data at 30-day follow-
up were available. The exclusion criteria were patients in 
whom MCS was used to support high-risk percutaneous 
coronary intervention, and all settings other than cardio-
genic shock. Patients were followed for a 30-day period 
after MCS device placement. The project was approved 
by the ethics committees of all participating centers and 
complied with the principles of the Helsinki Declaration 
(2008 revision). Written informed consent was obtained 
from all patients or, if the patient was in no clinical condi-
tion to provide consent, from a legal guardian or next of 
kin.
Indications and management of MCS
Temporary MCS was indicated for patients with car-
diogenic shock and persistent hemodynamic instabil-
ity despite initial management with vasopressors and/or 
revascularization when needed. Hemodynamic instabil-
ity was defined as a systolic blood pressure ≤ 90 mmHg 
despite inotrope/vasopressor support, signs of end-organ 
failure (clammy skin, capillary filling time > 3  s, urine 
output < 0.5 mL/kg/h, lactate level > 4 mmol/L), and low 
cardiac output (< 2.2 L/min/m2 if receiving inotropes/
vasopressors or < 1.8  L/min/m2 without inotropes/
vasopressors).
Impella  CP® (Abiomed Europe GmbH, Aachen, Ger-
many) and VA-ECMO (MAQUET Holding B.V.& Co. 
KG, Rastatt, Germany) were available at all centers. 
Among patients with clinical indications for MCS, the 
etiologies of cardiogenic shock included acute myocar-
dial infarction, acute decompensated heart failure, post-
cardiotomy shock, primary allograft dysfunction after 
heart transplantation, and myocarditis. Selection of the 
MCS device and overall patient management were left at 
the discretion of each center, according to clinical indica-
tion and center experience. All participating centers were 
trained in MCS indication and management according to 
current guidelines and ELSO (Extracorporeal Life Sup-
port Organization) [16].
Lactate measurement
All serum lactate levels were measured in arterial blood 
gas samples. Baseline lactate was defined as the last lac-
tate level measured before device implantation. Any lev-
els prior to that were not considered for analysis. Lactate 
levels after MCS were measured at predetermined time 
points (1  h, 6  h, 12  h, and 24  h after device implanta-
tion). For imputation of missing lactate values (10%), the 
mean between the preceding and subsequent available 
time points was used. Lactate clearance was determined 
by the following formula: [(lactate at time point of inter-
est − initial lactate)/initial lactate*100] [8].
Follow‑up and outcomes
All patients were followed after MCS weaning up to hos-
pital discharge. If it occurred before 30 days of follow-up, 
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patients were considered alive if reached by telephone or 
had a medical record within 30  days. The primary out-
come was defined as all-cause death. Survivors were 
defined as patients alive after 30 days weaned from MCS.
Statistical analysis
All continuous variables were tested for normality by the 
Shapiro–Wilk test and histogram analysis. If the assump-
tion of normality was rejected, data were reported as 
median [interquartile range (IQR)]. Categorical variables 
were expressed as number and percentage. A Mann–
Whitney test was used to compare lactate levels before 
and after MCS device implantation. The chi-square test 
was used to compare categorical variables. For evalua-
tion of prognostic value, the probability of death during 
follow-up was estimated for initial, 1  h, 6  h, 12  h, 24  h 
and overall effect for lactate (in mmol/L) and lactate 
clearance (in %), with the use of univariable and multi-
variable logistic regression models. For the multivariable 
analysis, three logistic regression models were created 
with the following adjustment variables: (1) device type, 
pre-device cardiac arrest, and center; (2) age, device type, 
shock to support time, and center; (3) Simplified Acute 
Physiology Score III (SAPS3) and Sequential Organ 
Failure Assessment Score (SOFA) and center. We per-
formed a sensitivity analysis for lactate levels and lactate 
clearance missing inputs. All variables were tested for 
multicollinearity in the multivariable models by the vari-
ance inflation test. The receiver operating characteristic 
(ROC) curve was used to evaluate the ability of differ-
ent lactate levels to predict 30-day mortality. To identify 
lactate cutoff points, Youden’s J index was calculated as: 
J = sensitivity + (specificity − 1). Sensitivity (S) and posi-
tive predictive value (PPV) were calculated for the time 
points of interest. Time to event analysis was calculated 
with Kaplan–Meier curves for each cutoff of lactate level 
or lactate clearance. Patients were censored at death or 
30 days. Significance was accepted at P < 0.05 for all tests. 
Data were analyzed in SPSS, Version 20.0 for Windows 
(SPSS Inc., Chicago, IL, USA), and R software (R Foun-
dation for Statistical Computing, Vienna, Austria; http://
www.R-proje ct.org).
Results
The cohort comprised 48 patients, of whom 5 were 
excluded because the Impella  CP® was used during high-
risk percutaneous coronary intervention. Baseline char-
acteristics and clinical data of the 43 patients included in 
the analysis are summarized in Table 1. Patients enrolled 
at each center, their CS etiology and device employed are 
shown at Additional file  1: Table  S1. The median (IQR) 
age was 57.0 (42.0–63.0) years; 33 (77%) were male. Anal-
ysis of comorbidities showed history of hypertension in 
19 (44%), diabetes in 15 (35%), and glomerular filtration 
rate < 60 mL/min/1.73m2 in 27 patients (63%). The most 
common etiology of cardiogenic shock was acute myo-
cardial infarction, in 19 patients (44%), followed by acute 
decompensation of chronic heart failure in 10 (24%), 
primary graft failure in 4 (9%), cardiac arrest in 4 (9%), 
postcardiotomy shock in 3 (7%), pulmonary thromboem-
bolism in 2 (5%), and myocarditis in 1 (2%). VA-ECMO 
was used in 25 patients (58%), the Impella  CP® in 13 
(30%), and combined VA-ECMO with Impella  CP® in 
5 (12%). Median time from shock team consult to MCS 
deployment was 3.0 (1.0–16.5) hours, and the median 
duration of support was 2.0 (1.0–5.0) days. At MCS ini-
tiation, 33 patients (77%) were receiving norepinephrine, 
at a median dose of 0.5 (0.25–0.64) mcg.kg.min−1; the 
most commonly used inotrope was dobutamine (37% 
of patients), and its median dose was 5.2 (4.5–8.0) mcg.
kg.min−1. The median initial serum lactate level was 
6.1  mmol/L (2.8–11.5  mmol/L), and the central venous 
oxygen saturation was 68.0% (54.0–74.6%).
At 30-day follow-up, 24 (56%) patients died on MCS, 
19 (44%) were weaned from MCS, and 12 (28%) were 
discharged from hospital and were alive at 30-day follow 
up. Risk scores for patients treated with MCS were calcu-
lated at admission. Specific scores for cardiogenic shock 
treated with MCS (such as SAVE score and ENCOUR-
AGE score) and a general intensive care unit (ICU) score 
(SOFA) did not differ between groups and were not asso-
ciated with 30-day mortality in the logistic regression 
models. However, SAPS 3, a general ICU score, differed 
between survivors and non-survivors (61.0 [58.2–70.0] 
vs. 72.0 [67.0–88.0], P = 0.01) and predicted 30-day mor-
tality in unadjusted analysis (OR = 1.01; CI 1.00–1.02, 
P = 0.002). The predicted mortality calculated through 
these risk scores ranged from 55 to 85% [17–20].
Lactate levels and lactate clearance as predictors 
of mortality
Lactate levels were associated with different odds ratios 
(ORs) of mortality across time points, with a progres-
sive increase in OR over time and the greatest magnitude 
at 24  h in the unadjusted model with similar trends in 
the adjusted models. The OR for overall effect of lactate 
ranged from 1.26 to 1.73 across adjusted models. Lac-
tate clearance was significantly associated with mortality 
only after 6  h, in both unadjusted and adjusted mod-
els (Table  2). The unadjusted analysis of the variables 
included in the models are shown in Additional file  1: 
Table  S2. Sensitive analyses of serum lactate and lac-
tate clearance for missing inputs showed similar results 
(Additional file 1: Table S3), as well as the sensitive anal-
ysis for cardiogenic shock etiology (Additional file  1: 
Table S4).
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Figure  1 depicts lactate levels and lactate clearance at 
baseline MCS, 1 h, 6 h, 12 h, and 24 h. Survivors showed 
a trend toward lower initial lactate levels in comparison 
to non-survivors (4.0 [2.6–6.3] mmol/L vs. 7.5 [2.8–12] 
mmol/L; P = 0.09). Lactate levels first rose in the first 
hour post-MCS placement, decreasing in subsequent 
hours. Significant differences between survivors and 
non-survivors was observed at 6 h (2.4 [1.7–6.2] mmol/L 
vs. 5.9 [2.6–15.0] mmol/L; P = 0.02), 12  h (1.8 [1.3–2.6] 
mmol/L vs. 4.0 [1.6–14.3] mmol/L; P = 0.02), and 
24  h (1.3 [1.1–2.3] mmol/L vs. 3.5 [1.6–13.3] mmol/L; 
P = 0.001, Additional file 1: Table S5). Both survivors and 
non-survivors were able to clear lactate levels over time, 
but a statistically significant difference between them was 
seen only at 24 h (60.3% [42.5 to 72.8%] for survivors vs. 
18.9% [− 50.0 to + 68.2%] for non-survivors, P = 0.04). 
After 24  h of MCS, 12 patients (28%) had higher lac-
tate levels than at baseline. Decannulation (2 [17%] vs. 
Table 1 Demographic and  clinical data of  43 patients with  cardiogenic shock who received mechanical circulatory 
support with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or an Impella  CP® device
COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation; ENCOURAGE, prediction of cardiogenic shock outcome for acute 
myocardial infarction patients salvaged by VA-ECMO; IQR, interquartile range (p25–p75); MCS, mechanical circulatory support; SAPS 3, Simplified Acute Physiology 
Score III; SAVE, Survival After Veno-arterial ECMO score; SOFA, Sequential Organ Failure Assessment score; VA, veno-arterial
a Score ranges from -15 to 15, with higher scores indicating lower mortality. For example, a score of -9 is associated with 70% mortality [17]
b Score ranges from 0 to 28, with higher scores indicating higher mortality. For example, a score of 23.5 is associated with 76% mortality at 30 days [18]
c Score ranges from 0 to 207, with higher scores indicating higher mortality. For example, a score of 70 is associated with 55% in-hospital mortality [19]







Clinical and demographic data
 Age, years, median (IQR) 57.0 (43.0 to 63.0) 57.0 (42.5 to 61.5) 59.0 (46.0 to 64.0)
 Male sex (%) 33 (76.7) 9 (75.0) 24 (77.4)
 Hypertension (%) 29 (67.4) 5 (41.6) 24 (77.4)
 Diabetes mellitus (%) 15 (34.8) 1 (8.3) 14 (45.1)
 COPD (%) 3 (6.9) 0 (0) 3 (9.6)
 Pre-device cardiac arrest (%) 14 (32.5) 6 (50) 8 (25.8)
Etiology of cardiogenic shock
 Acute myocardial infarction (%) 19 (44.1) 6 (50) 13 (41.9)
 Acute decompensation of chronic heart failure (%) 10 (23.2) 2 (16.6) 8 (25.8)
 Primary transplant graft failure (%) 4 (9.3) 2 (16.6) 2 (6.4)
 Cardiac arrest (%) 4 (9.3) 1 (8.3) 3 (9.6)
 Postcardiotomy syndrome (%) 3 (6.9) 0 (0) 3 (9.6)
 Pulmonary thromboembolism (%) 2 (4.6) 0 (0) 2 (6.4)
 Myocarditis (%) 1 (2.3) 1 (8.3) 0 (0)
Device characteristics
 VA-ECMO (%) 25 (58.1) 6 (50.0) 19 (61.2)
 Impella  CP® (%) 13 (30.2) 5 (41.6) 8 (25.8)
 VA-ECMO + Impella® (%) 5 (11.6) 1 (8.3) 4 (12.9)
 Shock to support time, hours, median (IQR) 3.0 (1.0 to 16.5) 3.5 (2.25 to 20.5) 2.5 (1.0 to 16.5)
 Time on support, days. median (IQR) 2.0 (1.0 to 5.0) 2.0 (1.25 to 3.0) 2.0 (1.0 to 6.0)
Critical illness variables
 Arterial lactate, mmol/L, median (IQR) 6.1 (2.8 to 11.5) 4.0 (2.62 to 6.3) 7.5 (2.8 to 12.0)
 Serum creatinine, mg/dL, median (IQR) 1.5 (1.1 to 1.8) 1.4 (0.8 to 1.8) 1.5 (1.2 to 1.8)
 Arterial pH, median (IQR) 7.29 (7.23 to 7.34) 7.28 (7.23 to 7.34) 7.31 (7.22 to 7.37)
 Arterial  HCO3, mEq/L, median (IQR) 18.7 (15.0 to 22.0) 17.6 (14.0 to 22.1) 18.8 (15.3 to 22.4)
 Central venous oxygen saturation, %, median (IQR) 68.0 (54.0 to 74.6) 68.0 (54.0 to 83.1) 64.4 (56.9 to 72.9)
 SAVE score, median (IQR)a − 9.0 (− 11.0 to 0) − 8.9 (− 10.0 to 3.0) − 9.0 (− 11.0 to − 1.2)
 ENCOURAGE score, median (IQR)b 23.5 (18.5 to 28.0) 24.0 (12.0 to 26.0) 23.0 (19.0 to 28.0)
 SAPS 3 score, median (IQR)c 70.0 (60.0 to 84.0) 61.0 (58.2 to 70.0) 72.0 (67.0 to 88.0)
 SOFA score, median (IQR)d 13.0 (10.0 to 15.0) 11.5 (10.0 to 14.7) 13.0 (10.0 to 15.0)
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17 [55%], P = 0.02) and mortality rates (12 [100%] vs. 19 
[61%], P = 0.01) differed significantly between patients 
who failed to clear lactate after 24 h versus those whose 
serum lactate improved during the first 24 h.
Prediction of 30‑day mortality
Lactate levels and lactate clearance showed an increase 
in area under the ROC curve (AUC) over time, with the 
Table 2 Association of serum lactate levels and clearance with 30-day mortality in unadjusted and adjusted analyses
CI, confidence interval; OR, odds ratio
a Model 1: adjusted by type of device (ECMO or Impella), pre-device cardiac arrest, center
b Model 2: adjusted by age, type of device (ECMO or Impella), shock to support time, center
c Model 3: adjusted by SOFA, SAPS 3, center
d There was no evidence of multicollinearity as assessed by the variance inflation test
e Overall lactate represents the mean serum lactate effect (1 h, 6 h, 12 h, 24 h) on 30-day mortality
f Clearance was calculated as the following: [(lactate at time point of interest – initial lactate)/initial lactate*100]
g All lactate clearance models were adjusted for initial lactate levels
Unadjusted Adjusted (model 1)a,d Adjusted (model 2)b,d Adjusted (model 3)c,d
OR 95% CI P OR 95% CI P OR 95% CI P OR 95% CI P
Lactate, baseline 1.15 1.00–1.39 0.04 1.13 0.98–1.37 0.09 1.19 1.01–1.48 0.03 1.21 1.01–1.55 0.03
Lactate, 1 h 1.13 1.00–1.33 0.05 1.11 0.97–1.32 0.14 1.21 1.02–1.50 0.02 1.29 1.07–1.73 0.005
Lactate, 6 h 1.18 1.03–1.47 0.01 1.16 1.01–1.45 0.03 1.27 1.07–1.64 0.004 1.34 1.10–1.95 0.01
Lactate, 12 h 1.27 1.05–1.76 0.005 1.25 1.04–1.74 0.01 1.46 1.13–2.22 0.001 1.62 1.19–3.03 < 0.001
Lactate, 24 h 1.76 1.13–4.33 0.001 1.63 1.11–3.88 0.001 2.37 1.24–6.90 < 0.001 5.86 1.53–67.86 < 0.001
Overall  lactatee 1.27 1.06–1.70 0.03 1.26 1.04–1.71 0.01 1.54 1.16–2.50 < 0.001 1.73 1.20–3.48 < 0.001
Clearance,  1hf,g 1.00 0.98–1.01 0.60 1.00 0.98–1.01 0.81 0.99 0.97–1.01 0.31 0.99 0.97–1.01 0.10
Clearance,  6hf,g 0.98 0.97–0.99 0.01 0.98 0.97–0.99 0.01 0.97 0.95–0.99 0.002 0.97 0.94–0.99 0.002
Clearance,  12hf,g 0.98 0.96–0.99 0.006 0.98 0.96–0.99 0.005 0.97 0.94–0.99 < 0.001 0.97 0.93–0.99 < 0.001
Clearance,  24hf,g 0.95 0.91–0.98 < 0.001 0.95 0.90–0.99 < 0.001 0.94 0.87–0.98 < 0.001 0.97 0.78–0.98 < 0.001
Fig. 1 Differences in lactate levels at the time points of interest between survivors and non-survivors. Legend: The box plot inner horizontal 
lines indicate median; boxes, interquartile range (25th and 75th percentiles); vertical whiskers, 1.5 interquartile range beyond the 25th and 75th 
percentiles; and dots, more extreme values
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greatest AUC at 24  h, but lactate levels showed better 
prognostic performance (Table 3).
Youden’s J index was calculated only at time points of 
lactate levels or clearance which differed significantly 
between survivors and non-survivors. Serum lactate 
thresholds were identified at 6  h (3.27  mmol/L; S: 71%, 
PPV: 85%), at 12 h (3.15 mmol/L; S: 65%, PPV: 91%), and 
at 24  h (1.55 mmol/L: S: 81%, PPV 86%). The threshold 
for lactate clearance at 24 h was 46.5% (S: 74%, PPV: 66%). 
Kaplan–Meier survival curves for each of the lactate and 
clearance thresholds identified are shown in Fig. 2.
Discussion
In this observational study of patients in cardiogenic 
shock treated with MCS, both serum lactate levels and 
lactate clearance were associated with 30-day mortal-
ity. In unadjusted and adjusted analyses, lactate levels 
at all time points and lactate clearance after 6  h were 
Table 3 Receiver operating characteristic curves 
for  prediction of  30-day mortality with  lactate levels 
and lactate clearance
AUC, area under the curve; CI, confidence interval
a AUC: < 0.2 poor, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 good, 0.81–1.00 
very good
AUC a CI P
Lactate, baseline 0.66 0.49–0.83 0.09
Lactate, 1 h 0.64 0.47–0.81 0.14
Lactate, 6 h 0.71 0.55–0.87 0.02
Lactate, 12 h 0.72 0.57–0.88 0.02
Lactate, 24 h 0.81 0.67–0.94 0.002
Clearance, 1 h 0.43 0.23–0.62 0.49
Clearance, 6 h 0.65 0.48–0.82 0.11
Clearance, 12 h 0.64 0.48–0.80 0.13
Clearance, 24 h 0.70 0.55–0.85 0.004
Fig. 2 Kaplan–Meier curves of survival in groups stratified by lactate cutoff levels determined with Youden’s J statistic for area under the ROC curve. 
a Lactate at 6 h ≤ 3.27 mmol/L; b Lactate at 12 h ≤ 3.15 mmol/L; c Lactate at 24 h ≤ 1.55 mmol/L; d Lactate clearance at 24 h ≥ 46.5%
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associated with mortality. Also, levels of serum lactate at 
6 h, 12 h, 24 h and its clearance after 24 h were able to 
discriminate survivors from non-survivors in our cohort. 
These data demonstrate that lactate measurements may 
be of greater prognostic value than the amount of lac-
tate cleared for a specific time point, although greater 
clearance was indeed associated with lower mortality. In 
addition, failure to clear baseline lactate levels after 24 h 
of MCS treatment was associated with 100% mortality. 
These findings may have practical implications regarding 
support strategies.
Serum lactate is a well-known outcome predictor in 
conditions associated with impaired tissue perfusion, 
such as cardiogenic shock [21, 22]. A cohort study of 
patients with cardiogenic shock who received percuta-
neous extracorporeal life support, mainly in the post-
cardiopulmonary resuscitation setting, found that initial 
lactate level was able to discriminate survivors from non-
survivors, after multivariable analysis [23]. These results, 
however, are in disagreement with previous studies [5, 8, 
22]. The discrepancy in association of initial lactate levels 
with mortality may reflect time from insult to initiation 
of mechanical support, differences in shock etiology, and 
differences in comorbidity profile. In our cohort, unad-
justed and adjusted analysis showed that the initial lac-
tate level was associated with mortality. In this cohort, 
the median initial arterial lactate was 6.1  mmol/L (2.8–
11.5 mmol/L). This value is supported by the literature as 
a threshold to trigger MCS, however, this cutoff is sup-
ported only by expert opinion. Previous cohorts of MCS 
patients have shown higher initial lactate levels, ranging 
from 7 to 14 mmol/L in the survival group than the one 
found in our study (4.0; 2.62 to 6.3), which may reflect 
a distinct population [5, 8, 14, 24]. Differences found in 
baseline lactate between survivors and non-survivors 
(4.0 vs. 7.5 mmol/L) in our study may be related to dis-
tinct cardiogenic shock etiologies and a higher burden of 
comorbidities such as hypertension and diabetes. How-
ever, survivors were more likely to have primary trans-
plant graft failure and postcardiotomy syndrome, that 
are commonly associated with higher lactate levels due to 
the surgical insult. Despite these discrepancies, shock to 
support time, a possible cause for distinct initial lactate 
levels, and the cardiogenic shock risk scores SAVE and 
ENCOURAGE were similar between groups at baseline.
The improvement in lactate level after initiation of 
MCS reflects a hemodynamic response, and may have 
greater prognostic utility than initial lactate levels. How-
ever, there is no consensus regarding optimal clearance 
of lactate within time. Our study was the first to show 
that lactate early as 6  h can discriminate survivor from 
non-survivors. Also, different from previous studies that 
focused on specific cardiogenic shock etiologies, our 
results show that in several clinical scenarios the lactate 
levels in 6  h, 12  h, and 24  h can discriminate survivors 
from non-survivors. Indeed, lactate levels at 24 h was a 
better mortality predictor. This discriminatory power of 
the lactate over time, as shown in Table 3, is probably due 
to the improvement in tissue perfusion provided by clini-
cal and MCS treatment. However, despite the improve-
ment in arterial lactate over time, non-survivors still 
showed a higher level after 24 h [3.5 (1.6–13.3)] mmol/L 
in comparison to survivors 1.3 (1.1–2.3) mmol/L. These 
failure to decrease lactate levels in the same amount as 
the survivors may be related to other organ damage and 
not only by a direct effect of the lactate molecule. Differ-
ences in absolute lactate and in lactate clearance between 
survivors and non-survivors were found only after 12  h 
of support in a cohort of VA-ECMO with multiple eti-
ologies [8]. Another recent study also highlighted differ-
ences in lactate levels in time, but failed to demonstrate 
any association of lactate clearance at 24 h with mortality 
[14]. However, it included a large number of postcardi-
otomy patients and did not include any with acute myo-
cardial infarction, which may explain the different results 
found in our study. These data highlights that not only 
clearance, but also a lactate reduction to a normal level is 
associated with better outcomes.
Besides the lack of data in cardiogenic shock supported 
by MCS, the use of initial arterial lactate and its clearance 
have been used as an end-point for a better tissue perfu-
sion in this scenario [25]. Initial studies on extracorporeal 
circulation demonstrated an association with inflam-
matory cytokines elevation due to the interaction of the 
blood with the device [26]. Similar concerns were raised 
on the use of ECMO for respiratory support in patients 
with COVID, where a cytokine storm have been reported 
[27]. Although the Impella catheter have a smaller con-
tact surface in comparison to VA-ECMO, it produces a 
greater shear stress due to its axial pump design leading 
to hemolysis [9, 28, 29]. In addition, both devices were 
indicated for different cardiogenic etiologies as shown in 
Additional file 1: Table S1. In the attempt to evaluate the 
association of the device used (VA-ECMO or Impella CP) 
with the lactate levels, we included it in two out of three 
adjusted analysis, which showed similar results. These 
results highlight that, despite the possibility of some 
interaction with the device or the underlying condition, 
lactate level under MCS showed an expected kinetic and 
can be used as a prognostic biomarker.
Few interventions are able to change outcomes in car-
diogenic shock. Refractory shock still carries high mor-
tality rates despite MCS [30]. In this setting, lactate cutoff 
points can be a useful tool in the decision-making pro-
cess. In an analysis of a cardiogenic shock registry, ini-
tial lactate greater than 4.0 mmol/L was associated with 
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a sevenfold increase in mortality, and was proposed 
as a threshold for MCS escalation in the authors’ pro-
tocol [31]. Fux et  al. [32] showed that an initial serum 
lactate greater than 15.0  mmol/L was associated with 
100% mortality in the setting of refractory postcardi-
otomy shock. Fortunately, extremely high initial lactate 
is quite uncommon. In our cohort, the median initial 
lactate was 6.1 mmol/L. This median level is within the 
range where MCS may be considered (over 4.0 and 
below 11.0 mmol/L), i.e., not in the extremes where MCS 
may no longer be useful. Also, we showed that the 24 h 
lactate levels had clear prognostic significance; each 
mmol/L increase in lactate was associated with a 1.76-
fold increase in mortality on adjusted analysis, rising up 
to 5.86-fold in a multivariable model. Youden’s J index 
identified clinically useful cutoff points: serum lactate 
levels below 3.27  mmol/L at 6  h, 3.15  mmol/L at 12  h, 
1.55 mmol/L at 24 h, and a 24 h lactate clearance of 46.5% 
predicted better survival. Moreover, failure to improve 
lactate at 24 h was associated with only 17% decannula-
tion, but 100% mortality, in this cohort. A similar trend 
was seen in a recent cohort of cardiogenic shock patients 
treated with IABP, where a lactate of 3.1  mmol at 8  h 
was the best predictor [13]. These data have the poten-
tial to affect bedside clinical decisions. Both VA-ECMO 
and Impella  CP® are costly interventions, which require 
rational use to be cost-effective [33]. Not only are the 
initial costs of the devices themselves high, but their use 
may entail additional procedures that are needed to sup-
port a critical patient, such as continuous hemodialysis, 
antibiotic therapy, mechanical ventilation, and prolonged 
ICU stay. If failure to improve lactate level after 24  h 
have such a clinical impact, and it is validated by further 
studies, it should be incorporated to the clinical decision 
process.
Rational decisions regarding implantation and wean-
ing of MCS devices are paramount determinants of the 
treatment success rates and financial sustainability of 
critical care programs. In this scenario, it is reasonable to 
use lactate as a biomarker to assess disease severity. Lac-
tate has all the characteristics of a good biomarker: it is 
widely available as a point-of-care test, inexpensive, and 
noninvasively measured. However, it should always be 
used in light of the clinical data available, never as a sin-
gle variable.
Study strengths and limitations
The strengths of this study rely on its multicentric 
design and the fact that all centers had uniform train-
ing on the use of MCS devices. Moreover, to the best of 
our knowledge, this is the first study to measure lactate 
kinetics using both VA-ECMO and Impella  CP®. Data 
on the use of MCS devices in low- and middle-income 
countries are scarce, and their cost-effectiveness in this 
scenario is yet to be established. Our study design has 
several limitations. This is a non-planned retrospective 
analysis from a cohort of MCS in cardiogenic shock. The 
four centers enrolled are not considered high volume for 
MCS in cardiogenic shock and it may have an impact 
in the indication and management of the cases. Due to 
the small cohort size, lactate kinetics could not be ana-
lyzed separately for each shock etiology or device. The 
choice of VA-ECMO or Impella  CP® implantation fol-
lowed local protocols, which took into account several 
clinical characteristics in the decision process other than 
initial lactate levels alone. Center-specific protocols may 
have differed regarding vasopressor support, fluid resus-
citation, and other clinical management decisions that 
can influence lactate levels and the patient outcomes. 
Higher lactate levels in the non-survivor group may have 
reflected underlying disease severity rather than failure 
to clear lactate while on MCS. Finally, the high mortality 
rate seen in our cohort also may have been attributable 
to illness severity, which may have affected the results 
of analysis. More studies are warranted to improve our 
understanding of lactate kinetics on cardiogenic shock 
and its role as a prognostic marker.
Conclusion
Arterial lactate is a biomarker currently used to assess 
prognosis in patients with cardiogenic shock treated with 
MCS devices (ECMO and Impella  CP®). The evaluation 
of lactate kinetics in this scenario showed a stronger rela-
tionship with 30-day mortality with the absolute lactate 
levels after 6 h of support in relation to lactate clearance 
in 24  h. The best prognostic ability was associated with 
absolute lactate levels at 24 h.
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